ReNerve (ASX:RNV) is working with US-based Berkeley Biologics to develop and commercialize two new tissue-based product ranges, according to a Monday filing with the Australian bourse.

The companies entered an initial five-year supply agreement for the product ranges, with the possibility of extension, as part of the collaboration, the filing said.

ReNerve plans to launch the first product line in the third quarter of the year and the second before the year ends, according to the filing.